Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 13/20 | 0.55 |
| ▸ | DRD2 | P14416 | 5/20 | 0.55 |
| ▸ | DRD4 | P21917 | 1/20 | 0.55 |
| ▸ | DRD1 | P21728 | 6/20 | 0.54 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25225949 | 0.84 | KDM4E (0.59) | DRD3DRD2ALDH1A1 | |
| SCHEMBL15690244 | 0.80 | AOC3 (0.56) | DRD3DRD2DRD4DRD1AOC3 | |
| SCHEMBL22725992 | 0.80 | AOC3 (0.58) | DRD3DRD2DRD4AOC3 | |
| SCHEMBL15691861 | 0.80 | BCAT2 (0.47) | DRD3DRD2DRD4DRD1ACHE | |
| SCHEMBL5811132 | 0.80 | GRM5 (0.64) | DRD3DRD2DRD4DRD1ACHE | |
| SCHEMBL31134854 | 0.80 | GRM5 (0.64) | DRD3DRD2DRD4DRD1ACHE | |
| SCHEMBL7683501 | 0.80 | DRD3 (0.56) | DRD3DRD2DRD4DRD1ACHE | |
| SCHEMBL7686132 | 0.80 | DRD3 (0.53) | DRD3DRD2DRD4DRD1ACHE | |
| SCHEMBL30183479 | 0.80 | DRD3 (0.53) | DRD3DRD2DRD4DRD1ACHE | |
| SCHEMBL179076 | 0.79 | HTT (0.51) | DRD3DRD2DRD4DRD1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025875-A1 | A COMPOUND AS A THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| WO-2022057845-A1 | COMPOUND SERVING AS THYROID HORMONE β RECEPTOR AGONIST AND USES OF COMPOUND | 广东东阳光药业有限公司 | 2022-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025875-A1 | A COMPOUND AS A THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF | THRB, TSHR, THRA | DRD3 1151/4885DRD2 955/4885DRD4 1180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.